Prophylactic 5-Fr pancreatic duct stents are superior to 3-Fr stents: a randomized controlled trial.
about
Does rectal indomethacin eliminate the need for prophylactic pancreatic stent placement in patients undergoing high-risk ERCP? Post hoc efficacy and cost-benefit analyses using prospective clinical trial data.Placement of prophylactic pancreatic stents to prevent post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a meta-analysisPrevention of postendoscopic retrograde cholangiopancreatography pancreatitis: the endoscopic technique.Impact of pancreatic stent caliber on post-endoscopic retrograde cholangiopancreatogram pancreatitis rates in patients with confirmed sphincter of Oddi dysfunction.Endoscopic complications--avoidance and management.Endoscopic prevention of post-endoscopic retrograde cholangiopancreatography pancreatitisPreventing post-endoscopic retrograde cholangiopancreatography pancreatitis: what can be done?Management of Post-ERCP Pancreatitis.Post-endoscopic retrograde cholangiopancreatography complications: How can they be avoided?Rectal indomethacin alone versus indomethacin and prophylactic pancreatic stent placement for preventing pancreatitis after ERCP: study protocol for a randomized controlled trialPancreatic Stent or Rectal Indomethacin-Which Better Prevents Post-ERCP Pancreatitis?: A Propensity Score Matching Analysis.Sphincter of Oddi Dysfunction: Updates from the Recent Literature.Reducing the risk of post-endoscopic retrograde cholangiopancreatography pancreatitis.Pancreatic stents for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis should be inserted up to the pancreatic body or tail.Can papillary carcinomas be treated by endoscopic ampullectomy?
P2860
Q30573759-E6AFE3AE-8D47-4EA2-85D1-DF211ED7459DQ33735401-F366DC2E-B263-4077-A7F8-54ED3584F210Q33758897-B9BFC703-31AC-4027-A2FE-8D4C2DE8412BQ34155119-3D797DA7-55AB-4294-8193-B45DB5D3A47EQ34157933-A08FC08D-1CC6-46A7-B1FE-518755EB39C8Q34589736-0D008D6C-14D9-4D42-8FDA-67077FEACB9CQ35012013-030C228D-07EF-4AD5-B387-4633AC5048EAQ35151282-734C185C-0B67-4C93-9414-91F88D164EB2Q36041101-ADCD0BA5-5434-4398-BE3C-B067233A6256Q36651854-42D19432-81BE-46AE-A1F6-B6969F3FA28BQ37207062-4F98B8F5-E18B-451A-A8C7-287E9B4CD0F0Q38542904-2A7A4477-9F1C-42AF-9109-B286BFA7DFA2Q39388249-89F1C309-BB21-4637-9048-53EBCBDD3091Q55293391-556AEB26-21FD-4753-97F9-D069015C8DC0Q57644059-711E3D46-F922-46D9-8A62-115FB7977FF3
P2860
Prophylactic 5-Fr pancreatic duct stents are superior to 3-Fr stents: a randomized controlled trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Prophylactic 5-Fr pancreatic d ...... a randomized controlled trial.
@ast
Prophylactic 5-Fr pancreatic d ...... a randomized controlled trial.
@en
type
label
Prophylactic 5-Fr pancreatic d ...... a randomized controlled trial.
@ast
Prophylactic 5-Fr pancreatic d ...... a randomized controlled trial.
@en
prefLabel
Prophylactic 5-Fr pancreatic d ...... a randomized controlled trial.
@ast
Prophylactic 5-Fr pancreatic d ...... a randomized controlled trial.
@en
P2093
P2860
P356
P1433
P1476
Prophylactic 5-Fr pancreatic d ...... a randomized controlled trial.
@en
P2093
B J Elmunzer
C R Piraka
D P Normolle
E Zolotarevsky
E-J Wamsteker
H Myra Kim
J M Scheiman
M A Anderson
P S Schoenfeld
P2860
P304
P356
10.1055/S-0030-1256305
P577
2011-03-31T00:00:00Z